Tower Research Capital LLC (TRC) - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2024$587,854
+761.2%
14,303
+878.3%
0.01%
+400.0%
Q1 2024$68,261
+3.6%
1,462
+6.1%
0.00%
+100.0%
Q4 2023$65,896
-48.3%
1,378
-61.4%
0.00%
-75.0%
Q3 2023$127,378
-83.5%
3,573
-78.7%
0.00%
-84.6%
Q2 2023$773,554
+585925.8%
16,769
+408.6%
0.03%
+550.0%
Q1 2023$132
-71.2%
3,297
-66.7%
0.00%
-78.9%
Q4 2022$459
-99.8%
9,911
+41.5%
0.02%
+280.0%
Q3 2022$290,000
-8.5%
7,005
+32.1%
0.01%
-28.6%
Q2 2022$317,000
+21.9%
5,302
+48.6%
0.01%
+250.0%
Q1 2022$260,000
+20.4%
3,569
+38.6%
0.00%
-50.0%
Q4 2021$216,000
-31.9%
2,575
-26.9%
0.00%
-50.0%
Q3 2021$317,000
-72.7%
3,521
-71.1%
0.01%
-73.3%
Q2 2021$1,162,000
+133.8%
12,190
+179.6%
0.03%
+275.0%
Q1 2021$497,000
+13.7%
4,360
+38.0%
0.01%
-38.5%
Q4 2020$437,000
+5.6%
3,159
-37.3%
0.01%
+160.0%
Q3 2020$414,000
-23.8%
5,040
-27.4%
0.01%
-77.3%
Q2 2020$543,000
+1710.0%
6,940
+883.0%
0.02%
+1000.0%
Q4 2019$30,000
+2900.0%
706
+1976.5%
0.00%
Q3 2019$1,000
-85.7%
34
-69.1%
0.00%
Q2 2019$7,000
-86.0%
110
-83.2%
0.00%
-100.0%
Q3 2018$50,000
+6.4%
655
-35.2%
0.00%
-33.3%
Q4 2017$47,000
-66.2%
1,011
-61.3%
0.01%
-45.5%
Q3 2017$139,0002,611
+52120.0%
0.01%
Q2 2017$0
-100.0%
5
-98.9%
0.00%
-100.0%
Q4 2016$33,000
+175.0%
465
+181.8%
0.00%
+300.0%
Q3 2016$12,000
-7.7%
165
-38.7%
0.00%0.0%
Q2 2016$13,000
-63.9%
269
-53.1%
0.00%
-80.0%
Q1 2016$36,000
-34.5%
573
+17.9%
0.01%
-44.4%
Q4 2015$55,000
+1000.0%
486
+872.0%
0.01%
Q2 2015$5,000
-28.6%
50
-53.7%
0.00%
-100.0%
Q1 2015$7,000
+250.0%
108
+300.0%
0.00%
Q3 2014$2,000
-86.7%
27
-91.4%
0.00%
-100.0%
Q1 2014$15,0003140.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2023
NameSharesValueWeighting ↓
First Light Asset Management, LLC 217,459$24,760,0001.64%
Motley Fool Asset Management LLC 152,326$17,344,0001.25%
Rock Springs Capital Management LP 450,000$51,237,0001.12%
AtonRa Partners 21,017$2,393,0001.07%
SECTORAL ASSET MANAGEMENT INC 112,200$12,775,0000.97%
EMERALD ADVISERS, LLC 228,368$26,002,0000.94%
EMERALD MUTUAL FUND ADVISERS TRUST 239,023$27,215,0000.90%
FEDERATED HERMES, INC. 3,912,408$445,467,0000.86%
HealthCor Management, L.P. 207,610$23,638,0000.84%
Atika Capital Management LLC 66,000$7,515,0000.65%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders